DRMA — Dermata Therapeutics, Inc.
$0.7810-9.61%
Last close: · regular session
Pre-market $0.7440 -4.74% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for DRMA in the TickerWise workspace.
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 8
- Website: https://www.dermatarx.com
Latest SEC filings for DRMA
Latest DRMA news
- Dermata reports positive results from Tome skincare study By Investing.com
- Dermata Therapeutics, Inc. (DRMA) Reports Positive Cosmetic Study Results for Tome
- Dermata Therapeutics (DRMA) Drops 3.34% to $0.86 as Traders Eye $0.82 Support
- Dermata Therapeutics, Inc.: Dividend historical data and projections
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.